Antibody responses to a spore carbohydrate antigen as a marker of nonfatal inhalation anthrax in rhesus macaques

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 743-748

  Saile, Elke ^a   Boons, Geert Jan ^b   Buskas, Therese ^b   Carlson, Russell W ^b   Kannenberg, Elmar L ^b,d   Barr, John R ^c   Boyer, Anne E ^c   Gallegos Candela, Maribel ^c,e   Quinn, Conrad P ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX TOXIN LETHAL FACTOR; BACTERIUM ANTIBODY; BOVINE SERUM ALBUMIN; CARBOHYDRATE ANTIGEN; CIPROFLOXACIN; IMMUNOGLOBULIN G ANTIBODY; TRISACCHARIDE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIUM DETECTION; CONTROLLED STUDY; EXPOSURE; FEMALE; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHESUS MONKEY; SEROLOGY;

ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CARBOHYDRATES; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; PRIMATE DISEASES; SPORES, BACTERIAL;

EID: 79955707574     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00475-10     Document Type: Article

References (37)

1. Baggett, H. C., et al. 2005. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001. Clin. Infect. Dis. 41:991-997.
2. Boyer, A. E., et al. 2009. Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques. Infect. Immun. 77:3432-3441.
3. Daubenspeck, J. M., et al. 2004. Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium. J. Biol. Chem. 279:30945-30953.
4. Dewan, P. K., et al. 2002. Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg. Infect. Dis. 8:1066-1072.
5. Dhénin, S. G., V. Moreau, M. C. Nevers, C. Créminon, and F. Djedaïni-Pilard. 2009. Sensitive and specific enzyme immunoassays for antigenic trisaccharide from Bacillus anthracis spores. Org. Biomol. Chem. 7:5184-5199.
6. Dong, S., et al. 2008. Anthrose biosynthetic operon of Bacillus anthracis. J. Bacteriol. 190:2350-2359. (Pubitemid 351466330)
7. Dong, S., et al. 2010. Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis. J. Bacteriol. 192:5053-5062.
8. Doolan, D. L., et al. 2007. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J. Infect. Dis. 195:174-184.
9. Friedlander, A. M., et al. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1243.
10. Glomski, I. J., A. Piris-Gimenez, M. Huerre, M. Mock, and P. L. Goossens. 2007. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog. 3:e76.
11. Guidi-Rontani, C., M. Weber-Levy, E. Labruyère, and M. Mock. 1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31:9-17.
12. Han, C. S., et al. 2006. Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis. J. Bacteriol. 188:3382-3390.
13. Hanna, P. C., and J. A. Ireland. 1999. Understanding Bacillus anthracis pathogenesis. Trends Microbiol. 7:180-182.
14. Hsu, V. P., et al. 2002. Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg. Infect. Dis. 8:1039-1043.
15. International Office of Epizootics, World Health Organization, and Food and Agriculture Organization of the United Nations. 2008. Anthrax in humans and animals, 4th ed. World Health Organization, Geneva, Switzerland.
16. Jefferds, M. D., et al. 2002. Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg. Infect. Dis. 8:1138-1144.
17. Jernigan, D. B., et al. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis. 8:1019-1028.
18. Jernigan, J. A., et al. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944.
19. Kubler-Kielb, J., et al. 2008. Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component. Proc. Natl. Acad. Sci. U. S. A. 105:8709-8712.
20. Kuehn, A., et al. 2009. Development of antibodies against anthrose tetrasaccharide for specific detection of Bacillus anthracis spores. Clin. Vaccine Immunol. 16:1728-1737.
21. Mehta, A. S., et al. 2006. Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium. Chemistry 12:9136-9149. (Pubitemid 46008502)
22. Mock, M., and T. Mignot. 2003. Anthrax toxins and the host: a story of intimacy. Cell. Microbiol. 5:15-23.
23. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
24. Oberli, M. A., et al. 2010. Molecular analysis of carbohydrate-antibody interactions: case study using a Bacillus anthracis tetrasaccharide. J. Am. Chem. Soc. 132:10239-10241.
25. Preisz, H. 1909. Experimentelle Studien über Virulenz, Empfänglichkeit und Immunität beim Milzbrand. Z. Immunitä tsforschung. 5:341-452.
26. Quinn, C. P., et al. 2004. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J. Infect. Dis. 190:1228-1236.
27. Quinn, C. P., et al. 2002. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg. Infect. Dis. 8:1103-1110.
28. Ross, J. M. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J. Pathol. Bacteriol. LXXIII:485-494.
29. Sanderson, W. T., et al. 2004. Bacillus anthracis contamination and inhalational anthrax in a mail processing and distribution center. J. Appl. Microbiol. 96:1048-1056.
30. Shieh, W. J., et al. 2003. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am. J. Pathol. 163:1901-1910.
31. Smith, H., J. Keppie, and J. L. Stanley. 1955. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. anthracis in vivo. Br. J. Exp. Pathol. 36:460-472.
32. Stanley, J. L., and H. Smith. 1961. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26:49-63.
33. Steichen, C., P. Chen, J. F. Kearney, and C. L. Turnbough, Jr. 2003. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J. Bacteriol. 185:1903-1910.
34. Tamborrini, M., et al. 2009. Immuno-detection of anthrose containing tetrasaccharide in the exosporium of Bacillus anthracis and Bacillus cereus strains. J. Appl. Microbiol. 106:1618-1628.
35. Turnbull, P. C. B. 1998. Guidelines for the surveillance and control of anthrax in humans and animals, 3rd ed. World Health Organization, Geneva, Switzerland.
36. Welkos, S. L. 1991. Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb. Pathog. 10:183-198.
37. Werz, D. B., and P. H. Seeberger. 2005. Total synthesis of antigen Bacillus anthracis tetrasaccharide - creation of an anthrax vaccine candidate. Angew Chem. Int. Ed. Engl. 44:6315-6318.